TOKYO, July 11 (Reuters) - The Eisai executive who helped garner full U.S. approval for the Japanese drugmaker's Alzheimer's disease treatment Leqembi will retire at the end of this month, the company ...
TOKYO, July 11 (Reuters) - The Eisai executive who helped garner full U.S. approval for the Japanese drugmaker's Alzheimer's disease treatment Leqembi will retire at the end of this month, the company ...
The company achieved JPY 18.1 billion in cumulative results through the third quarter. The number of patients currently receiving treatment is approximately 13,500, and the cumulative number of ...
Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement ...
TOKYO (Reuters) -The Eisai executive who helped garner full U.S. approval for the Japanese drugmaker's Alzheimer's disease treatment Leqembi will retire at the end of this month, the company said on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results